Re: Results of novel strategies for treatment of Wilms' tumor

Abstract

sive-dose salvage chemotherapy regimes including ifosfamide, carboplatin and etoposide, as well as autologous hematopoietic stem-cell rescue (3). Further improvement in adjuvant therapy regimes can also be obtained by neoadjuvant chemotherapy, that concomitantly enables a technically easier and safer surgical removal of the tumor, without the risks and hazards of tumor spilage (4,5). The aim of clinical trials nowadays is to reduce chemotherapy for children with low-risk tumors, therefore reducing its side effects, and to improve it in patients with high-risk Wilms' tumor, including those with anaplastic, bilateral and recurrent tumors (1,6).